{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-030777","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.558504+00:00","generated_at":"2026-06-05T03:46:56.388597+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Akari Therapeutics to merge with Peak Bio; Akari to issue ~50% of post-merger ADSs","bullets":["Akari acquires Peak Bio via merger; Peak Bio survives as wholly-owned subsidiary.","Consideration: Akari ADSs representing ~50% of outstanding Akari ADSs post-closing, adjusted for net cash.","Voting agreements with ~39.5% of Akari shareholders and ~39.3% of Peak Bio stockholders to vote in favor.","Conditions include $10M PIPE investment, S-4 effectiveness, Nasdaq listing, and no material adverse effect.","Termination fee of $300,000 plus expense reimbursement up to $1.5 million under specified circumstances."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-030777","json":"https://secwatch.observer/filing/0001104659-24-030777.json","markdown":"https://secwatch.observer/filing/0001104659-24-030777.md","text":"https://secwatch.observer/filing/0001104659-24-030777.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000110465924030777/0001104659-24-030777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000110465924030777/tm247836d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T03:46:56.388597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb1c6611b6bc9fdd853823df8a5e854f68bac10c","claim":"Akari Therapeutics Plc entered into Agreement and Plan of Merger with Peak Bio, Inc. (effective 2024-03-04).","evidence_excerpt":"On March 4, 2024, Akari Therapeutics, Plc, a public company limited by shares incorporated in England and Wales (\" Akari \"), entered into an Agreement and Plan of Merger (the \" Merger Agreement \") with Peak Bio, Inc. (\" Peak Bio \") and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Akari (\" Merger Sub \")","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000110465924030777/0001104659-24-030777-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Peak Bio, Inc."},{"label":"Effective","value":"2024-03-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}